Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 6/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18198008 | 0.89 | CYP3A4 (0.52) | CA12CA2CA7CA9CA14 | |
| SCHEMBL18198005 | 0.89 | CYP3A4 (0.52) | CA12CA2CA7CA9CA14 | |
| SCHEMBL18198037 | 0.89 | CYP3A4 (0.52) | CA12CA2CA7CA9CA14 | |
| SCHEMBL7298468 | 0.89 | MMP2 (0.60) | CA12CA2CA7CA9CA14 | |
| SCHEMBL17323656 | 0.89 | MMP2 (0.60) | CA12CA2CA7CA9CA14 | |
| SCHEMBL16473194 | 0.84 | MMP2 (0.50) | CA12CA2CA7CA9CA14 | |
| SCHEMBL16380450 | 0.78 | MMP2 (0.79) | MMP2MMP9ADAMTS4ALDH1A1POLB | |
| SCHEMBL16252309 | 0.77 | LMNA (0.53) | NPC1RAB9AALDH1A1CTRB1LMNA | |
| SCHEMBL13233695 | 0.77 | LMNA (0.53) | NPC1RAB9AALDH1A1CTRB1LMNA | |
| SCHEMBL13750427 | 0.77 | MMP9 (0.65) | CA2CA7MMP2MMP9ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CA12 386/4885CA2 209/4885CA7 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.